Skip to main content
Close

LFA Collective Data Analysis Initiative

Developing new, safe, effective therapies for lupus is incredibly complex. In clinical trials, researchers face many obstacles that make it very difficult to show whether a potential treatment works or is better than the current treatment.

The goal of the Lupus Foundation of America's Collective Data Analysis Initiative (LFA CDAI) is to improve clinical trial design so new treatments can get to people who need them faster.

The LFA CDAI began in 2009 as a unique collaboration among multiple companies with a shared goal: to get new treatments to people with lupus.

LFA CDAI combines data from past lupus studies from around the world. LFA CDAI biostatisticians analyze the data to identify trends and gain new insights. The results help the entire lupus research community conduct clinical trials that produce more meaningful data. 

To date, LFA-CDAI has collected data from 10 different trials and published more than 13 abstracts and publications. Read the most recent publication, presented at the 2018 American College of Rheumatology Annual Conference.

For more information on the LFA CDAI, please contact Leslie Hanrahan, Vice President for Education and Research, at [email protected]